Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed and Gemcitabine in Advanced Urothelial Cancer
NCT00053209Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2004
- Primary completion
- Sep 2007
- Countries
- 1
- Sponsor
- Eastern Cooperative Oncology Group
- Modality
- Small Molecules
- Drugs
- pemetrexed
- Conditions
- urothelial carcinoma (UC)
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in urothelial carcinoma (UC), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Objective Response Rate and Toxicity. Started Aug 2004; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Pemetrexed + Gemcitabine
Pemetrexed disodium and gemcitabine combination chemotherapy
03
Who it enrols
Patients with histologically confirmed advanced urothelial cancer (TCC or mixed) who have not received prior systemic chemotherapy for metastatic disease. Must have adequate organ function and ECOG PS 0-2.
04
Endpoints
Primary
Objective Response Rate
Toxicity
Secondary
Time to Progression
Overall Survival
Beyond the preview
Go deeper on NCT00053209.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053209.